Amoxicillin

Generic Name: Amoxicillin

Brand Names: Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₉N_₃O_₅S

CAS Number: 26787-78-0

Unique Ingredient Identifier: 9EM05410Q9

Background: Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication: Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.

Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections

Clinical Trials

Vonoprazan for Helicobacter Pylori Eradication in Adolescents

Phase 3

Completed

Conditions: Treatment Effectiveness

Interventions: Drug: Vonoprazan
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Esomeprazole

First Posted Date: 2023-12-08

Last Posted Date: 2024-08-28

Lead Sponsor: Alexandria University

Target Recruit Count: 242

Registration Number: NCT06162949

Locations: 🇪🇬
Faculty of Medicine, Alexandria, Egypt

Choline to Improve Malnutrition and Enhance Cognition

Not Applicable

Recruiting

Conditions: Severe Acute Malnutrition
Cognitive Impairment
Kwashiorkor
Wasting

Interventions: Dietary Supplement: C-RUTF (Ready-to-Use Therapeutic Food with added choline)
Dietary Supplement: S-RUTF (Ready-to-Use Therapeutic Food without added choline)
Drug: Amoxicillin

First Posted Date: 2023-12-04

Last Posted Date: 2024-12-12

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 1500

Registration Number: NCT06154174

Locations: 🇲🇼
Makhwira, Makhwira, Chikwawa, Malawi
🇲🇼
Chikonde, Chikonde, Mulanje, Malawi
🇲🇼
Chipolonga, Chipolonga, Machinga, Malawi

and more 7 locations

Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice

Phase 3

Recruiting

Conditions: Periodontal Diseases
Periodontitis
Periodontal Pocket

Interventions: Other: Placebo
Drug: Amoxicillin
Drug: Metronidazole

First Posted Date: 2023-11-14

Last Posted Date: 2024-05-31

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 544

Registration Number: NCT06131021

Locations: 🇺🇸
University of Alabame, Birmingham, Alabama, United States

Combination Study of Antibiotics With Enzalutamide (PROMIZE)

Phase 1

Recruiting

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions: Drug: Enzalutamide 40mg
Drug: Amoxicillin 500mg
Drug: Metronidazole 400mg
Drug: Vancomycin 125mg
Drug: Ciprofloxacin 500g

First Posted Date: 2023-11-13

Last Posted Date: 2025-04-24

Lead Sponsor: Institute of Cancer Research, United Kingdom

Target Recruit Count: 39

Registration Number: NCT06126731

Locations: 🇨🇭
Oncolgy Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
🇬🇧
The Royal Marsden NHS Foundation Trust, London Borough of Sutton, United Kingdom